Simplify Asset Management Inc. Purchases 17,010 Shares of DexCom, Inc. (NASDAQ:DXCM)

Simplify Asset Management Inc. increased its position in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 372.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 21,574 shares of the medical device company’s stock after buying an additional 17,010 shares during the period. DexCom accounts for about 0.4% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 21st largest holding. Simplify Asset Management Inc.’s holdings in DexCom were worth $2,443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of DXCM. Mirae Asset Global Investments Co. Ltd. raised its holdings in DexCom by 31.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after acquiring an additional 65,516 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in DexCom by 3,596.7% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after purchasing an additional 1,079 shares during the last quarter. West Family Investments Inc. acquired a new stake in DexCom in the 1st quarter worth $209,000. Ergoteles LLC grew its position in DexCom by 60.6% in the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock worth $860,000 after purchasing an additional 634 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in DexCom by 26.4% in the 1st quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock worth $15,100,000 after purchasing an additional 6,160 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Insider Buying and Selling

In related news, Director Steven Robert Pacelli sold 5,442 shares of the business’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $116.40, for a total transaction of $633,448.80. Following the completion of the sale, the director now directly owns 138,129 shares of the company’s stock, valued at $16,078,215.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Steven Robert Pacelli sold 5,442 shares of the business’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $116.40, for a total transaction of $633,448.80. Following the completion of the sale, the director now directly owns 138,129 shares of the company’s stock, valued at $16,078,215.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 38,464 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $109.94, for a total transaction of $4,228,732.16. Following the transaction, the chief executive officer now owns 331,337 shares of the company’s stock, valued at approximately $36,427,189.78. The disclosure for this sale can be found here. Insiders sold a total of 141,835 shares of company stock valued at $16,443,758 over the last ninety days. Insiders own 0.41% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Raymond James raised their price target on shares of DexCom from $138.00 to $140.00 in a research report on Friday, April 28th. Barclays raised their price target on shares of DexCom from $110.00 to $115.00 in a research report on Monday, May 1st. Wolfe Research initiated coverage on shares of DexCom in a research report on Thursday, January 26th. They set an “outperform” rating and a $121.00 target price on the stock. UBS Group lifted their target price on shares of DexCom from $142.00 to $150.00 in a research report on Friday, April 28th. Finally, Stifel Nicolaus lifted their target price on shares of DexCom from $130.00 to $140.00 in a research report on Friday, April 28th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.81.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $0.49 during trading on Friday, reaching $114.12. The company had a trading volume of 503,904 shares, compared to its average volume of 2,326,922. DexCom, Inc. has a 52 week low of $67.11 and a 52 week high of $126.44. The stock has a market cap of $44.24 billion, a PE ratio of 163.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.82 and a current ratio of 2.02. The business’s 50 day moving average price is $117.86 and its 200-day moving average price is $114.51.

DexCom (NASDAQ:DXCM – Get Rating) last announced its earnings results on Thursday, April 27th. The medical device company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. DexCom had a net margin of 9.68% and a return on equity of 18.29%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $720.52 million. During the same period in the previous year, the firm posted $0.08 earnings per share. The company’s revenue was up 1085.0% on a year-over-year basis. Analysts expect that DexCom, Inc. will post 1.06 earnings per share for the current year.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.